article thumbnail

Does the pandemic mark a turning point in vaccine development?

pharmaphorum

After a period where vaccine development had fallen away, suddenly it is back in the limelight. However, for those individuals working on vaccine development, the pandemic has proven to be a validation of the important work being carried out in the field. billion from its vaccine in 2021. The ‘poor relation’.

article thumbnail

Influenza Activity and Vaccine Effectiveness During the 2021-2022 Season

Pharmacy Times

Influenza viruses typically circulate in the Northern Hemisphere during the winter and spring, but they occasionally can circulate more during the summer months, as did the 2009 H1N1 pandemic strain.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Race to the finish: pharma edges closer to approval with RSV vaccines

Pharmaceutical Technology

RSV researchers at major pharmaceutical companies are currently working to develop new RSV drugs to beat future waves of RSV infection and gain the first RSV vaccine FDA approval. During the 2009–19 period, children in the US ages five years and younger accounted for 58, 000 annual RSV-related hospitalisations and 100–500 annual deaths.

article thumbnail

Building agile partner relationships at a vaccine-focused biotech

pharmaphorum

In this episode of the pharmaphorum podcast series, Dr Paul Tunnah chats with Jeff Baxter, CEO of VBI Vaccines and Lee Taurman, executive vice president full service commercial at Syneos Health. Jeff Baxter – President and CEO, VBI Vaccines. Mr. Baxter joined VBI in September of 2009.

article thumbnail

Ph. Eur. rabbit pyrogen test replacement texts ready for public consultation

European Pharmaceutical Review

Replacing the rabbit pyrogen test The texts covering topics such as vaccines for human use, blood products, antibiotics, radiopharmaceuticals and containers, have now been revised to replace the RPT with an in vitro alternative, the monocyte activation test (MAT) or another animal welfare-compatible approach. General chapter 2.6.30.

article thumbnail

Paving the way for anti-Abeta active immunotherapy

European Pharmaceutical Review

Active anti-Abeta immunotherapies In the 2000s, the concept of active immunotherapy targeting Abeta in Alzheimer’s patients was assessed with the ELAN vaccine (AN1792), consisting of full-length aggregated Abeta 1-42 peptide mixed with the QS21 adjuvant. 8 However, as this trial was not placebo-controlled, conclusions are difficult to draw.

article thumbnail

Nine for 2021: The COVID-19 legacy

pharmaphorum

Anyone who proposed that a novel, deadly virus would spread, with a vaccine developed demonstrating 95% efficacy, and approved for patients in less than a year would have been scoffed at. These changes are likely to reduce only slowly in the Vaccine+ environment, and will not be entirely reversed.

Hospitals 105